We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery Disease

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: April 10, 2012
Last Update Posted: April 11, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
National Cheng-Kung University Hospital


The investigators examined whether rosiglitazone, a thiazolidinedione (TZD), is beneficial for pre-diabetes mellitus (DM) adults with documented coronary artery disease (CAD).


Microvascular and macrovascular complications are common in type 2 DM. There is no evidence about the effects of TZDs, synthetic peroxisome proliferator-activated receptor (PPAR)-γ activators (insulin sensitizers and adipose transcriptional regulation and anti-inflammatory process activators) on pre-DM patients with documented CAD.

Condition Intervention Phase
Prediabetes Coronary Artery Disease Insulin Resistance Glucose Intolerance Drug: placebo tablet Drug: rosiglitazone (4 mg)/day Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Role of Rosiglitazone Treatment and Secondary Prevention of Cardiovascular Events in Patients With Pre-Diabetes Mellitus and Coronary Artery Disease

Resource links provided by NLM:

Further study details as provided by National Cheng-Kung University Hospital:

Primary Outcome Measures:
  • major cardiovascular events, including myocardial infarction, overt heart failure, and surgery or coronary intervention for CAD [ Time Frame: at least 6 months follow-up of MACEs ]
    Primary end points: The primary end-point was defined as major cardiovascular events, including myocardial infarction, overt heart failure, and surgery or coronary intervention for CAD.

Secondary Outcome Measures:
  • Biomarkers measurements [ Time Frame: Biomarkers were taken before the trial and 6 months later ]

    Resistin and adiponectin will be measured to evaluate insulin resistance; CCL/MCP-1 and hsCRP were also analyzed to evaluate inflammation status changes.

    Several vascular associated remodeling markers and proteins will also be measured.

Enrollment: 105
Study Start Date: November 2006
Study Completion Date: July 2011
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: placebo Drug: placebo tablet
placebo tablet for 6 months
Experimental: rosiglitazone (4 mg)/day Drug: rosiglitazone (4 mg)/day
rosiglitazone (4 mg)/day for 6 months

Detailed Description:

Materials and Methods:

This is a randomized, double-blind, placebo-controlled study, patients will be randomly assigned to the TZD group and to the placebo group with a 6-month treatment period.

Biomarkers will also examined before and 6 months post-treatment during the trial.

The primary end-points will be the diagnosis of major cardiovascular events: myocardial infarction, overt heart failure, and surgery or coronary intervention for CAD.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • documented CAD by angiography
  • insulin resistance or glucose intolerance
  • 18 to 80 years of age

Exclusion Criteria:

  • under DM treatment
  • allergy to TZD
  • active inflammation
  • chronic disease under NSAID treatment
  • active heart failure
  • unwilling or unable to sign inform consents
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: National Cheng-Kung University Hospital
ClinicalTrials.gov Identifier: NCT01574820     History of Changes
Other Study ID Numbers: NCKUH HR95-10
First Submitted: April 4, 2012
First Posted: April 10, 2012
Last Update Posted: April 11, 2012
Last Verified: April 2012

Keywords provided by National Cheng-Kung University Hospital:
coronary artery disease
insulin resistance
glucose intolerance

Additional relevant MeSH terms:
Prediabetic State
Glucose Intolerance
Diabetes Mellitus
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Hypoglycemic Agents
Physiological Effects of Drugs